Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-07-08
2008-07-08
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S048000
Reexamination Certificate
active
11121169
ABSTRACT:
The present invention provides a therapeutic method for treating diabetic kidney disease, e.g., diabetic nephropathy that includes the administration of an effective amount of an A2Aadenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor.
REFERENCES:
patent: 6531457 (2003-03-01), Linden et al.
patent: WO-2005/107463 (2005-11-01), None
Okusa et al. Kidney International (2001), vol. 59, pp. 2114-2125.
Pflueger et al. Am. J. Physiol Renal Physiol. (1999), vol. 276, pp. 340-346.
“International Search Report for Application No. PCT/US05/15241”, (Aug. 19, 2005),3 pgs.
Okusa, M D., “Enhanced Protection from Renal Ischemia: Reperfusion Injury With A2A-Adenosine Receptor Activation and PDE 4 Inhibition”,Kidney International, 59(6), (2001),2114-2125.
Okusa, Mark D., “Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney”,Am. J. Physiol., vol. 277 (3, Pt 2), (1999),F404-F412.
Awad Alaa S.
Linden Joel M.
Macdonald Timothy L.
Okusa Mark D.
Lewis Patrick
Schwegman Lundberg & Woessner, P.A.
University of Virginia Patent Foundation
LandOfFree
Agonists of A2A adenosine receptors for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agonists of A2A adenosine receptors for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agonists of A2A adenosine receptors for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3945828